PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.00
Bid: 61.00
Ask: 64.00
Change: -1.40 (-2.24%)
Spread: 3.00 (4.918%)
Open: 61.00
High: 61.00
Low: 61.00
Prev. Close: 62.40
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PLACED IN TECHNOLOGY FAST 500 EMEA AWARDS

2 Jan 2018 07:00

RNS Number : 6349A
Novacyt S.A.
02 January 2018
 

FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS

 

Paris, France and Cambridge, UK - 2 January 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte's Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in Europe, the Middle East and Africa (EMEA).

 

Novacyt has delivered strong revenue growth averaging 113% between 2013 and 2016. In 2016, the Group generated revenues of €11.1 million on a consolidated basis, representing annual growth of 25%, with a 55% gross profit margin, which was an increase of seven percentage points on the previous year.

 

Graham Mullis, Group CEO of Novacyt, commented:

"We are delighted to once again be placed in the Technology Fast 500 EMEA awards. This year Novacyt has received its highest ever ranking. The commitment to our three core strategic pillars is enabling us to deliver strong growth and puts us on a pathway to sustainable profitability.

 

"I would like to thank all our employees for their dedication and commitment in driving our business forward culminating in this achievement and I look forward to updating shareholders of our full year 2017 sales later this month."

 

- End -

 

 

About Deloitte Global's 2017 Technology Fast 500 EMEA program

 

Deloitte Global's Technology Fast 500™ EMEA program is an objective industry ranking focused on the technology ecosystem. It recognizes technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past four years. The program is supported by Deloitte Global's Technology Fast 50 initiatives, which rank high-growth technology companies by location or specifically defined geographic area, and are run by Deloitte Global's Technology, Media & Telecommunications (TMT) industry group. More information on the program is available at www.deloitte.com/fast500emea 

 

Now in its seventeenth year, the Technology Fast 500 program in EMEA included over 18 countries, including Belgium, France, Finland, Germany, Italy, the Netherlands, Turkey and the UK. This year's winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016.

 

Sponsors of Deloitte Global's 2017 Technology Fast 500 EMEA program are Euronext, a pan-European exchange that helps tech companies finance growth and innovative projects through the stock market; Oracle NetSuite, provider of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries; and Michael Page, recognized by clients and candidates the world over as the leading specialist consultancy in permanent recruitment, temporary staffing and interim management.

 

 

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

 

For more information please refer to the website: www.novacyt.com 

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

 

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison

+44 (0)20 7610 7600

 

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com 

 

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASSDFMFFASESF
Date   Source Headline
14th Jun 20192:45 pmRNSConversion of Loan Notes
3rd Jun 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
24th May 20197:00 amRNSPublication of Annual Report and Notice of AGM
17th May 20194:35 pmRNSConversion of Loan Notes
15th May 20195:30 pmRNSConversion of Loan Notes
13th May 20197:00 amRNSLaunch of Next-Generation qPCR Instrument
3rd May 20196:23 pmRNSConversion of Loan Notes
3rd May 20197:00 amRNSChange of Adviser
1st May 20195:30 pmRNSLiquidity Agreement
30th Apr 20197:00 amRNSFull Year 2018 Results
25th Apr 20197:00 amRNSUpdate on Notice of Full Year Results
23rd Apr 20197:00 amRNSConvertible Bond Facility
8th Apr 20197:00 amRNSExpanded Development Partnership with Immunexpress
1st Apr 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
4th Mar 20197:00 amRNSLiquidity Agreement and Total Voting Rights
26th Feb 20197:00 amRNSFunding Update
1st Feb 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
22nd Jan 20197:00 amRNSRevenues Full Year 2018
2nd Jan 201912:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Dec 20187:00 amRNSTrading Update
21st Dec 20187:00 amRNSNovacyt launches two new molecular diagnostic kits
11th Dec 20187:00 amRNSUpdate on Strategic Review
6th Dec 20187:00 amRNSCompletion of q16 molecular diagnostics order
3rd Dec 20181:00 pmRNSLiquidity Agreement and Total Voting Rights
30th Nov 201812:06 pmRNSReplacement: Unsecured Debt Facility
27th Nov 20187:00 amRNS$3.0M supply agreement with Genesis Diagnostics
1st Nov 20185:45 pmRNSLiquidity Agreement
1st Oct 201810:51 amRNSLiquidity Agreement and Total Voting Rights
26th Sep 20187:00 amRNSNovacyt Half Year 2018 Results
13th Sep 20187:00 amRNSNovacyt Partners with Applied Microarrays
3rd Sep 201811:15 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 201810:30 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 20187:00 amRNSHalf Year Revenue Update
26th Jul 20187:00 amRNSRevenue update to be announced on 2 August 2018
2nd Jul 201811:45 amRNSLiquidity Agreement Update and Total Voting Rights
28th Jun 20187:00 amRNSAcquisition of ID Business from Omega Diagnostics
12th Jun 201811:45 amRNSReplacement - Results of Annual General Meeting
12th Jun 20187:00 amRNSResults of Annual General Meeting
5th Jun 20187:00 amRNSLaunch of New Product in Infectious Mononucleosis
1st Jun 20183:30 pmRNSLiquidity Agreement and Total Voting Rights
30th May 20186:30 pmRNSNew Unsecured Debt Facility
23rd May 20182:51 pmRNSPublication of Annual Report and Notice of AGM
1st May 20184:30 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Apr 20187:00 amRNSNovacyt Full Year 2017 Results
3rd Apr 20181:30 pmRNSLiquidity Agreement Update and Total Voting Rights
22nd Mar 20187:00 amRNSSigning of Assay Development Contract with GenePOC
1st Mar 20182:59 pmRNSLiquidity Agreement Update and Total Voting Rights
1st Feb 20183:15 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Jan 20189:32 amRNSNotification of major holdings
24th Jan 20187:00 amRNSNOVACYT REVENUES FULL YEAR 2017

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.